Synergistic anticancer effects of everolimus (RAD001) and Rhein on gastric cancer cells via phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Ye T, Yang M, Huang D, et al. MicroRNA-7 as a potential therapeutic target for aberrant NF-κB-driven distant metastasis of gastric cancer. J Exp Clin Cancer Res. 2019;38(1):55.
   PubMed Web of Science ®Google Scholar
• Liu C, Yang G, Liu N, et al. Effect of lncRNA BNC2-AS1 on the proliferation, migration and invasion of gastric cancer cells. Clin Lab. 2018;64(11). DOI:10.7754/Clin.Lab.2018.180537
   Web of Science ®Google Scholar
• Zhang W, Wang Y, Zhu Z, et al. Propofol inhibits proliferation, migration and invasion of gastric cancer cells by up-regulating microRNA-195. Int J Biol Macromol. 2018;120(P A):975–984.
   PubMedGoogle Scholar
• Silva G, Teixeira Lima F, Seba V, et al. Curcumin analog CH-5 suppresses the proliferation, migration, and invasion of the human gastric cancer cell line HGC-27. Molecules. 2018;23(2):279.
   PubMed Web of Science ®Google Scholar
• Katai H, Ishikawa T, Akazawa K, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese gastric cancer association (2001-2007). Gastric Cancer. 2018;21(1):144–154.
   PubMed Web of Science ®Google Scholar
• Sharma M, Duan Z, Zhao H, et al. Real-world patterns of everolimus use in patients with metastatic breast cancer. Oncologist. 2020;25(11):937.
   PubMed Web of Science ®Google Scholar
• Sheng X, Yan X, Chi Z, et al. Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. EBioMedicine. 2020;55:102755.
   PubMed Web of Science ®Google Scholar
• El Dika I, Mayer RJ, Venook AP, et al. A multicenter randomized three-arm phase II study of (1) everolimus, (2) estrogen deprivation therapy (EDT) with leuprolide + letrozole, and (3) everolimus + EDT in patients with unresectable fibrolamellar carcinoma. Oncologist. 2020;25(11):925.
   PubMed Web of Science ®Google Scholar
• Lang SA, Gaumann A, Koehl GE, et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer. 2007;120(8):1803–1810.
   PubMed Web of Science ®Google Scholar
• Huang YK, Kang WM, Ma ZQ, et al. NUCKS1 promotes gastric cancer cell aggressiveness by upregulating IGF-1R and subsequently activating the PI3K/Akt/mTOR signaling pathway. Carcinogenesis. 2019;40(2):370–379.
   PubMed Web of Science ®Google Scholar
• Cejka D, Preusser M, Woehrer A, et al. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biol Ther. 2008;7(9):1377–1385.
   PubMed Web of Science ®Google Scholar
• Taguchi F, Kodera Y, Katanasaka Y, et al. Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination. Invest New Drugs. 2011;29(6):1198–1205.
   PubMed Web of Science ®Google Scholar
• Cao Y, Qu J, Li C, et al. Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway. Tumour Biol. 2015;36(7):5607–5615.
   PubMedGoogle Scholar
• Liu H, Yao Y, Zhang J, et al. MEK inhibition overcomes everolimus resistance in gastric cancer. Cancer Chemother Pharmacol. 2020;85(6):1079–1087.
   PubMed Web of Science ®Google Scholar
• Li X, Liu Y, Zhao Y, et al. Rhein derivative 4F inhibits the malignant phenotype of breast cancer by downregulating Rac1 protein. Front Pharmacol. 2020;11::754.
   Web of Science ®Google Scholar
• Ma Y-L, Chen F, Shi J. Rhein inhibits malignant phenotypes of human renal cell carcinoma by impacting on MAPK/NF-κB signaling pathways. Onco Targets Ther. 2018;11::1385–1394.
   Web of Science ®Google Scholar
• Lee SJ, Lee J, Lee J, et al. Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. Invest New Drugs. 2013;31(6):1580–1586.
   PubMed Web of Science ®Google Scholar
• Yoon DH, Ryu MH, Park YS, et al. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer. 2012;106(6):1039–1044.
   PubMed Web of Science ®Google Scholar
• Kang W, Zheng X, Wang P, et al. Deguelin exerts anticancer activity of human gastric cancer MGC-803 and MKN-45 cells in vitro. Int J Mol Med. 2018;41(6):3157–3166.
   PubMed Web of Science ®Google Scholar
• Xu T, Liu P, Li Q, et al. Inhibitory effects of everolimus in combination with paclitaxel on Adriamycin-resistant breast cancer cell line MDA-MB-231. Taiwanese J Obstetrics Gynecol. 2020;59(6):828–834.
   PubMed Web of Science ®Google Scholar
• Ni T, Wang H, Li D, et al. Huachansu Capsule inhibits the proliferation of human gastric cancer cells via Akt/mTOR pathway. Biomed Pharmacothe. 2019;118:109241.
   PubMed Web of Science ®Google Scholar
• Yan XY, Zhang JJ, Zhong XR, et al. The LINC00365/SCGB2A1 (mammaglobin B) axis down-regulates NF-κB signaling and is associated with the progression of gastric cancer. Cancer Manag Res. 2020;12::621–631.
   Web of Science ®Google Scholar
• Zhang W, Niu J, Ma Y, et al. The synergistic antitumor activity of chidamide in combination with bortezomib on gastric cancer. Onco Targets Ther. 2020;13::3823–3837.
   Web of Science ®Google Scholar
• Yuan G, Ding W, Sun B, et al. Upregulated circRNA_102231 promotes gastric cancer progression and its clinical significance. Bioengineered. 2021;12(1):4936–4945.
   PubMed Web of Science ®Google Scholar
• Liu Z, Cai C, Du J, et al. TCMIO: a comprehensive database of traditional chinese medicine on immuno-oncology. Front Pharmacol. 2020;11::439.
   Web of Science ®Google Scholar
• Liu J, Yan S, Hu J, et al. MiRNA-4537 functions as a tumor suppressor in gastric cancer and increases the radiosensitivity of gastric cancer cells. Bioengineered. 2021;12(1):8457–8467.
   PubMed Web of Science ®Google Scholar
• Ge H, Tang H, Liang Y, et al. Rhein attenuates inflammation through inhibition of NF-κB and NALP3 inflammasome in vivo and in vitro. Drug Des Devel Ther. 2017;11::1663–1671.
   Web of Science ®Google Scholar
• Lin ML, Chung JG, Lu YC, et al. Rhein inhibits invasion and migration of human nasopharyngeal carcinoma cells in vitro by down-regulation of matrix metalloproteinases-9 and vascular endothelial growth factor. Oral Oncol. 2009;45(6):531–537.
   PubMed Web of Science ®Google Scholar
• Chen J, Luo B, Wen S, et al. Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug. Invest New Drugs. 2020;38(3):755–764.
   PubMed Web of Science ®Google Scholar
• Li Y, Xu Y, Lei B, et al. Rhein induces apoptosis of human gastric cancer SGC-7901 cells via an intrinsic mitochondrial pathway. Braz J Med Biol Res. 2012;45(11):1052–1059.
   PubMed Web of Science ®Google Scholar
• Lorenzen S, Stahl M, Hofheinz RD, et al. Influence of taxanes on treatment sequence in gastric cancer. Oncol Res Treat. 2020;43(1–2):42–47.
   PubMed Web of Science ®Google Scholar
• Du C, Li D-Q, Li N, et al. DDX5 promotes gastric cancer cell proliferation in vitro and in vivo through mTOR signaling pathway. Sci Rep. 2017;7:42876.
   PubMed Web of Science ®Google Scholar
• Yang L, Lin S, Kang Y, et al. Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway. J Exp Clin Cancer Res. 2019;38(1):31.
   PubMedGoogle Scholar
• Zhuang Y, Bai Y, Hu Y, et al. Rhein sensitizes human colorectal cancer cells to EGFR inhibitors by inhibiting STAT3 pathway. Onco Targets Ther. 2019;12::5281–5291.
   Web of Science ®Google Scholar
• Han NN, Li X, Tao L, et al. Doxorubicin and rhein loaded nanomicelles attenuates multidrug resistance in human ovarian cancer. Biochem Biophys Res Commun. 2018;498(1):178–185.
   PubMed Web of Science ®Google Scholar
• Shen Z, Zhu B, Li J, et al. Rhein augments antiproliferative effects of atezolizumab based on breast cancer (4T1) regression. Planta Med. 2019;85(14–15):1143–1149.
   PubMed Web of Science ®Google Scholar
• D-z X, Q-r G, Tian Y, et al. Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer. BMC Cancer. 2010;10::536.
   Web of Science ®Google Scholar
• Wang A, Jiang H, Liu Y, et al. Rhein induces liver cancer cells apoptosis via activating ROS-dependent JNK/Jun/caspase-3 signaling pathway. J Cancer. 2020;11(2):500–507.
   PubMed Web of Science ®Google Scholar
• Shi P, Huang Z, Chen G. Rhein induces apoptosis and cell cycle arrest in human hepatocellular carcinoma BEL-7402 cells. Am J Chin Med. 2008;36(4):805–813.
   PubMed Web of Science ®Google Scholar
• Jiang C, Ma Z, Zhang G, et al. CSNK2A1 promotes gastric cancer invasion through the PI3K-Akt-mTOR signaling pathway. Cancer Manag Res. 2019;120::10135–10143.
   Google Scholar
• Lee HJ, Venkatarame Gowda Saralamma V, Sm K, et al. Pectolinarigenin induced cell cycle arrest, autophagy, and apoptosis in gastric cancer cell via PI3K/AKT/mTOR signaling pathway. Nutrients. 2018;10(8):1043.
   PubMed Web of Science ®Google Scholar
• Cai C, Dang W, Liu S, et al. Anthrax toxin receptor 1/tumor endothelial marker 8 promotes gastric cancer progression through activation of the PI3K/AKT/mTOR signaling pathway. Cancer Sci. 2020;111(4):1132–1145.
   PubMed Web of Science ®Google Scholar
• Chen H, Guan R, Lei Y, et al. Lymphangiogenesis in gastric cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis. BMC Cancer. 2015;15::103.
   Web of Science ®Google Scholar
• Cao G-D, Chen K, Chen B, et al. Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients. BMC Cancer. 2017;17(1):841.
   PubMedGoogle Scholar
• Wu C, Cao H, Zhou H, et al. Research progress on the antitumor effects of rhein: literature review. Anticancer Agents Med Chem. 2017;17(12):1624–1632.
   PubMed Web of Science ®Google Scholar
• Bu T, Wang C, Jin H, et al. Organic anion transporters and PI3K–AKT–mTOR pathway mediate the synergistic anticancer effect of pemetrexed and rhein. J Cell Physiol. 2020;235(4):3309–3319.
   PubMed Web of Science ®Google Scholar
• Chen D, Lin X, Zhang C, et al. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway. Cell Death Dis. 2018;9(2):123.
   PubMedGoogle Scholar